Eric Green

Eric Green leads West Pharmaceutical Services as Chairman and CEO, overseeing the company that manufactures the critical containment and delivery components found inside virtually every injectable drug in the world. When a nurse draws medicine from a vial, the rubber stopper was likely made by West. When a patient self-injects a biologic therapy using a prefilled syringe or autoinjector, the elastomeric components and often the device itself were made by West. West's products are classified as primary packaging — components that directly contact the drug and are therefore subject to rigorous pharmaceutical regulatory requirements. Changing a primary packaging component requires expensive and time-consuming regulatory filings, creating enormous switching costs. Once a drug is approved with West components, they are essentially locked in for the product's commercial life. The biologics revolution has been a powerful tailwind: biologic drugs (antibodies, cell therapies, gene therapies) are more sensitive than traditional small molecules and require higher-quality containment — premium West products like NovaPure and Flurotec-coated components. Key stock drivers include injectable drug market growth, biologics development pipeline, COVID vaccine booster demand normalization, Proprietary Products segment margins, high-value product adoption, customer inventory destocking cycles, competition with Datwyler and Aptar Pharma, and the overall trajectory of injectable drug administration.